Over the past 3 months, 10 analysts have published their opinion on Alnylam Pharmaceuticals ALNY stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
|Bullish||Somewhat Bullish||Indifferent||Somewhat Bearish||Bearish|
In the last 3 months, 10 analysts have offered 12-month price targets for Alnylam Pharmaceuticals. The company has an average price target of $192.7 with a high of $400.00 and a low of $96.00.
Below is a summary of how these 10 analysts rated Alnylam Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
This current average represents a 1.12% decrease from the previous average price target of $194.88.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.